-Press release from Campaign for Judicial Accountability and Reforms   The problem of judicial delays has recently gained public attention in light of the impassioned appeal by the Chief Justice of India to the Government, at the Joint Conference of Chief Ministers and Chief Justices on 24 April 2016, to increase the strength of judges and clear all pending files relating to judicial appointments. The Chief Justice of India also appealed to...

-The Indian Express Never before has India’s agricultural science community been as demoralised as now Everyone knows Indian agriculture is in deep crisis, impacting around 115 million farmers and an equal number of landless cultivators. Two consecutive bad monsoons and falling commodity prices have resulted in the imports of edible oils and pulses touching all-time-highs, even as its exports of agri-products — from basmati rice, soya meal, sugar, milk powder and...

-The Hindu Business Line The absence of a strong framework can hold up productivity improvements. But GEAC is better than having no regulator at all The clamour for the state to regulate (as against the powers of the legally mandated regulatory agency), field trials of bio-technology seeds for cotton and then mustard, is truly extraordinary. It has serious long-term consequences for the economy. The challenges to the Genetic Engineering Advisory Council’s powers to regulate the...

-The Times of India NEW DELHI: The total period of trial in corruption cases will not exceed four years with a special judge initially required to wind up proceedings in two years itself. Thereafter the trial can be extended, subject to six-month extension, states the Prevention of Corruption (Amendment) Bill, 2015 currently before the Rajya Sabha. The bill also stipulates recording of reasons for any delay in trial beyond two years and includes...

-The Times of India NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease. The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction...